De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era

Hepatology - United States
doi 10.1002/hep.30045
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy

Clinical Liver Disease
Hepatology
2019English

Hepatitis C Related Hepatocellular Carcinoma in the Era of Direct-Acting Antivirals

Hepatoma Research
2018English

Direct Acting Antiviral Regimens Usher in the Era of HCV Positive Donors in Lung Transplant

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2019English

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

Frontiers in Medicine
Medicine
2019English

Response To: Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antiviral Drug

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2016English

Hepatocellular Carcinoma Mechanisms Associated With Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

Journal of Hepatocellular Carcinoma
2020English

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma

Cancers
Cancer ResearchOncology
2019English

Two Cases of Hepatocellular Carcinoma Occurring Immediately After Direct-Acting Antiviral Agents Against Hepatitis C Virus

Internal Medicine
Internal MedicineMedicine
2019English

Direct-Acting Antivirals and Recurrence of Hepatocellular Carcinoma

Liver Transplantation
HepatologyTransplantationSurgery
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy